<DOC>
	<DOCNO>NCT02031042</DOCNO>
	<brief_summary>The purpose study investigate sentinel lymph node biopsy reliable stag tool breast cancer patient plan neoadjuvant chemotherapy ( =before breast surgery ) , case , safe omit axillary lymph node dissection sentinel lymph node free metastasis .</brief_summary>
	<brief_title>Sentinel Node Biopsy Before and/or After Neoadjuvant Chemotherapy Breast Cancer</brief_title>
	<detailed_description>Sentinel lymph node biopsy ( SLNB ) introduce late 1990Â´s become standard procedure stag axilla early stage breast cancer associate significantly less arm morbidity axillary lymph node dissection ( ALND ) . Neoadjuvant chemotherapy ( NAC ) give breast surgery indicate locally advanced breast cancer increasingly use early stage breast cancer purpose downstaging tumor thereby possibly enable breast conserving surgery . Traditionally , standard axillary stag tool ALND although 50 per cent patient diagnosis metastasis axillary lymph node . In addition , NAC eradicate metastasis axillary lymph node 40 per cent patient . SLNB therefore evaluate neoadjuvant setting NAC still controversial timing debate . This Swedish prospective multi-institutional study without comparison goup . The comparison finding SLNB follow ALND perform NAC patient . If patient clinically node-negative diagnosis SLNB perform ( without frozen section ) NAC ( substudy I ) . The reason repeat SLNB NAC 1 ) find happens NAC 2 ) possible identify repeat SLNB 3 ) reliable . If patient node-positive diagnosis ( cytologically verify lymph node metastasis ) SLNB perform NAC together breast operation ALND ( substudy II ) . When SLNB perform NAC , sentinel lymph node also analyse frozen section order validate method chemotherapy . Both blue dye radiolabelled isotope localisation sentinel lymph node recommend lymphoscintigraphy optional . All consecutive clinically node-negative ( unclear nodal status ultrasound cytology ) patient plan NAC oral write information study responsible surgeon . After accept participate , patient ask sign write consent . Patients cytologically verify lymph node metastasis/es diagnosis inform ask participate substudy II completion NAC . According statistical analysis , expect loss 10 per cent , sample size 220 patient need substudy I show false negative rate le 10 per cent . If include 200 patient 50 per cent lymph node positive diagnosis estimation false negative rate base 100 individual . If estimate true false negative rate 8 per cent , precision 80 per cent power +/- 7 per cent unit ( 2-sided test 95 per cent confidence interval ) . The Central Contact ( PI ) responsible data collection , management analysis . Each protocol send together write consent copy relevant histopathological report PI , control miss incongruent data , ask responsible investigator institution/hospital complement miss data patient journal ( copy medical record histopathological report ) .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>clinically nodenegative ( unclear nodal status ) substudy I sign consent study participant inflammatory breast cancer cytologically verify lymph node metastasis/es diagnosis ( substudy I ) , patient include substudy II patient able give inform consent hypersensitivity allergy blue dye isotope</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>neoadjuvant chemotherapy</keyword>
	<keyword>breast cancer</keyword>
	<keyword>sentinel lymph node biopsy</keyword>
	<keyword>false negative rate</keyword>
	<keyword>identification rate</keyword>
</DOC>